10x Genomics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Serge Saxonov
- Full Time Employees
- 1,306
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 6230 Stoneridge Mall Road Pleasanton CA United States of America 94588-3260
- IPO Date
- Sep 12, 2019
- CIK
- 0001770787
- Website
- 10xgenomics.com
- Similar Companies
- Business
- 10x Genomics, Inc. (NASDAQ: TXG) develops and sells instruments, consumables, and software for analyzing biological systems at the single-cell and spatial level. The company offers Chromium instruments and single cell gene expression, immune profiling, ATAC-seq, and multiome analysis kits; Visium and Xenium platforms for spatial gene expression and protein analysis; and GEM-X technology for enhanced single-cell resolution; as well as bioinformatics software including Cell Ranger, Loupe Browser, and Space Ranger. Headquartered in Pleasanton, California, and founded in 2012, 10x Genomics operates globally, serving academic institutions, biotechnology firms, pharmaceutical companies, and clinical research organizations primarily in North America, Europe, and Asia. In recent developments, the company launched GEM-X in late 2023, significantly improving single-cell capture efficiency and data quality for genomic applications; expanded its Xenium in situ platform with Xenium Prime for high-throughput spatial biology workflows; and strengthened its capabilities through strategic collaborations with leading biotech firms on multi-omics research initiatives. These advancements position 10x Genomics at the forefront of the spatial genomics and single-cell sequencing segments within the life sciences tools industry.
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript
10x Genomics Q1 Earnings Call Highlights
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10x Genomics Reports First Quarter 2026 Financial Results
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor
10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
Analyzing Hinge Health (NYSE:HNGE) and 10x Genomics (NASDAQ:TXG)
10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026